Vital Therapies Inc (NASDAQ:VTL)’s share price dropped 9.8% during mid-day trading on Friday . The company traded as low as $0.21 and last traded at $0.21. Approximately 820,495 shares traded hands during trading, a decline of 46% from the average daily volume of 1,514,334 shares. The stock had previously closed at $0.23.
VTL has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Vital Therapies from a “buy” rating to a “hold” rating in a research report on Saturday, November 17th. ValuEngine cut shares of Vital Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Seven analysts have rated the stock with a hold rating, Vital Therapies has an average rating of “Hold” and a consensus target price of $12.00.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Monday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter.
A number of hedge funds and other institutional investors have recently made changes to their positions in VTL. SG Americas Securities LLC acquired a new position in Vital Therapies in the 4th quarter valued at approximately $37,000. Two Sigma Investments LP increased its position in Vital Therapies by 42.5% in the 4th quarter. Two Sigma Investments LP now owns 208,872 shares of the company’s stock valued at $39,000 after acquiring an additional 62,284 shares during the period. Virtu Financial LLC increased its position in Vital Therapies by 120.3% in the 4th quarter. Virtu Financial LLC now owns 310,499 shares of the company’s stock valued at $58,000 after acquiring an additional 169,530 shares during the period. Geode Capital Management LLC increased its position in Vital Therapies by 99.7% in the 4th quarter. Geode Capital Management LLC now owns 682,934 shares of the company’s stock valued at $127,000 after acquiring an additional 340,970 shares during the period. Finally, Vanguard Group Inc increased its position in Vital Therapies by 11.1% in the 3rd quarter. Vanguard Group Inc now owns 1,481,908 shares of the company’s stock valued at $408,000 after acquiring an additional 148,016 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Vital Therapies (VTL) Shares Down 9.8%” was reported by WKRB News and is the property of of WKRB News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.wkrb13.com/2019/03/17/vital-therapies-vtl-shares-down-9-8.html.
Vital Therapies Company Profile (NASDAQ:VTL)
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Read More: Net Margin
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.